VLA‐4 antagonists: Potent inhibitors of lymphocyte migration
VLA‐4 antagonists: Potent inhibitors of lymphocyte migration
复制标题
VLA-4 拮抗剂：淋巴细胞迁移的有效抑制剂
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
W. Hagmann
中科院分区：
文献类型：
--
作者：
Ginger X. Yang;W. Hagmann
作为免疫监视过程的重要成员，循环淋巴细胞通常以相对低的数量通过血管外空间迁移。也就是说，直到内皮细胞接收到潜在感染或炎症状态的信号。这些血管表面细胞反过来过表达并呈递循环淋巴细胞粘附分子的配体。当遇到这种更高密度的配体时，原本沿着血管表面悠闲滚动的淋巴细胞现在变得更加牢固地附着，改变形状，并通过紧密连接迁移到感染或炎症部位。如果起始事件没有解决并且病症变成慢性的，则可能存在淋巴细胞的持续外渗，这可能加剧炎性病症，这反过来将继续招募更多的炎性细胞，导致不必要的组织破坏。正是为了减弱这种持续的炎症细胞募集周期，正在开发极晚期活化抗原-4（VLA-4）拮抗剂。除中性粒细胞外，大多数淋巴细胞在其表面表达VLA-4，并与内皮血管细胞粘附分子-1（VCAM-1）相互作用。VLA-4拮抗剂旨在破坏这种相互作用，从而结束慢性炎症的循环，这是许多疾病的标志。本综述将提供自2001年初以来出现的VLA-4拮抗剂的更新，并将讨论在其开发中可能遇到的一些问题，包括积极和消极的问题。© 2003 Wiley Periodicals，Inc. Med Res Rev，23，No. 3，369 - 392，2003
Circulating lymphocytes normally migrate through extravascular spaces in relatively low numbers as important members of the immunosurveillance process. That is until signals are received by endothelial cells that there is an underlying infection or inflammatory condition. These vascular surface cells in turn overexpress and present ligands to circulating lymphocyte adhesion molecules. Upon encountering this higher density of ligands, lymphocytes, which had been leisurely rolling along the vascular surface, now become more firmly attached, change shape, and migrate through tight junctions to the sites of infection or inflammation. If the initiating events are not resolved and the condition becomes chronic, there can be a sustained extravasation of lymphocytes that can exacerbate the inflammatory condition, which in turn will continue to recruit more inflammatory cells resulting in unwanted tissue destruction. It is for the attenuation of this cycle of sustained inflammatory cell recruitment that very late activating antigen‐4 (VLA‐4) antagonists are being developed. Most lymphocytes, except neutrophils, express VLA‐4 on their surface and they interact with endothelial vascular cell adhesion molecule‐1 (VCAM‐1). It is this interaction that VLA‐4 antagonists are intended to disrupt, thus, putting an end to the cycle of chronic inflammation, which is the hallmark of many diseases. This review will provide an update of VLA‐4 antagonists that have appeared since early 2001 and will discuss some of the issues, both positive and negative, that may be encountered in their development. © 2003 Wiley Periodicals, Inc. Med Res Rev, 23, No. 3, 369‐392, 2003
登录
查看更多内容
调节骨髓中 B 淋巴细胞生成的细胞和分子。
影响因子：
29.7
作者：
Kincade,PW;Lee,G;Pietrangeli,CE;Hayashi,S;Gimble,JM
通讯作者：
Gimble,JM
DOI：
10.1073/pnas.90.20.9374
发表时间：
1993-10-15
影响因子：
11.1
作者：
PAPAYANNOPOULOU, T;NAKAMOTO, B
通讯作者：
NAKAMOTO, B
DOI：
--
发表时间：
1993
期刊：
The Journal of biological chemistry
影响因子：
--
作者：
Masumoto,A;Hemler,ME
通讯作者：
Hemler,ME
T 细胞上表达的高亲和力极晚期抗原 4 亚群对于自发粘附强化是必需的，但对于剪切流中 VCAM-1 上的滚动而言不是必需的。
DOI：
--
发表时间：
1999
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Chen,C;Mobley,JL;Dwir,O;Shimron,F;Grabovsky,V;Lobb,RR;Shimizu,Y;Alon,R
通讯作者：
Alon,R
影响因子：
7.7
作者：
X. D. Yang;H. Sytwu;H. Mcdevitt;S. Michie
通讯作者：
X. D. Yang;H. Sytwu;H. Mcdevitt;S. Michie